Inactive Instrument

Analyst Reco. Mereo BioPharma Group PLC London S.E.

Equities

Needham Adjusts Price Target on Mereo BioPharma to $6 From $5, Keeps Buy Rating	Mar. 28	MT
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)	23-10-14	CI
Shift to Fed's Rate Hike Path, Better Outlook on UBS-Credit Suisse Deal Pushes US Equities Up	23-03-21	MT
European Equities Move Lower Following ECB Rate Hike	23-02-02	MT
SVB Securities Trims Price Target on Mereo BioPharma Group to $4 From $8, Maintains Outperform Rating	22-11-10	MT
Cantor Fitzgerald Starts Mereo BioPharma Group at Overweight With $4 Price Target	22-08-12	MT
Needham Adjusts Price Target on Mereo BioPharma Group to $5 From $10, Reiterates Buy Rating	22-06-06	MT
MEREO BIOPHARMA : BTIG Initiates Mereo BioPharma at Buy Rating With $10 Price Target	21-05-05	MT
MEREO BIOPHARMA : Needham Starts Mereo BioPharma Group at Buy With $10 Price Target	21-04-05	MT

No results for this search